Douglas F. Kling
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.
Journal: Nature medicine
Published: April 17, 2026
Obicetrapib safety analysis: Pooled phase 3 clinical trial experience.
Journal: American journal of preventive cardiology
Published: February 28, 2026
Cholesteryl ester transfer protein inhibition with obicetrapib is associated with attenuated decline in kidney function in patients at high cardiovascular risk: Post hoc pooled results from the BROADWAY and BROOKLYN trials.
Journal: American journal of preventive cardiology
Published: February 20, 2026
Efficacy of Obicetrapib Across the Spectrum of Background Lipid-Lowering Therapies: Pooled Analyses of the BROADWAY and BROOKLYN Randomized Trials.
Journal: European journal of preventive cardiology
Published: November 18, 2025
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.
Journal: European heart journal
Published: September 29, 2025
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.
Journal: The journal of prevention of Alzheimer's disease
Published: August 19, 2025
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
Journal: Journal of the American College of Cardiology
Published: June 30, 2025
A Drug-Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: May 14, 2025
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
Journal: The New England journal of medicine
Published: May 08, 2025
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 05, 2025
Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non-human primate studies and clinical trials.
Journal: Pharmacology research & perspectives
Published: July 25, 2024
Last Updated: 09/26/2026